

Unidades Investigadoras

1. Diabetes y enfermedad Cardiovascular
 - a. Estudio SAVOR: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-357
 - b. Estudio HARMONY: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet, Volume 392, Issue 10157, 1519 - 1529
 - c. Estudio SURPASS: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClinicalTrials.gov ID NCT04255433
2. Enfermedad coronaria estable:
 - a. Estudio ISCHEMIA: Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med 2020;382:1395-1407
3. Sobrepeso - Obesidad y enfermedad Cardiovascular:
 - a. Estudio SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-223
4. Registros EUROASPIRE:
 - a. IV, V y VI: <https://www.escardio.org/Research/registries/global-registries-and-surveys-programme/euroaspire-vi>
5. Programa REVIDAS:
 - a. REcuperación Vascular Integral. Abordaje multiDiscipinar en Aterosclerosis Sintomática. Creación de una Unidad de Recuperación Vascular